M3DIMAKER FOR ORAL TAILORED-DOSE THERAPIES – A NEW EMERGING TECHNOLOGY FOR PERSONALIZED Review analysis by Saptadeep Nandi

 M3DIMAKER:



A Game Changer in Personalized Medicine

Personalized medicine is the future of healthcare, where treatments are tailored to the unique needs of each patient. M3DIMAKER is a cutting-edge technology that revolutionizes the way oral tailored-dose therapies are developed and delivered.

Advantages of M3DIMAKER:

1.      Precision Dosing: M3DIMAKER utilizes 3D printing technology to create precise doses of medication tailored to each patient's unique needs

2.      Improved Patient Outcomes: By delivering the right dose of medication to the right patient at the right time, M3DIMAKER has the potential to improve patient outcomes and reduce the risk of adverse reactions.

3.      Cost-effective: By reducing the need for multiple clinical trials and reducing the time it takes to bring personalized medicines to market, M3DIMAKER can help lower the cost of developing new treatments.

4.      Easy to Use: M3DIMAKER is user-friendly and easy to use, making it accessible to a wide range of healthcare providers, including hospitals, clinics, and pharmacists.


The need for the study of M3DIMAKER:

       1. Safety and Efficacy: M3DIMAKER is a new technology and its safety and efficacy need to be thoroughly tested and established through clinical trials.

1.      Optimization of Dosing: Further studies are necessary to optimize the dosing and delivery of medications using M3DIMAKER technology.

2.      Comparison to Conventional Methods: Studies are required to compare the effectiveness and safety of M3DIMAKER to conventional methods of delivering medication, such as traditional pill forms or liquid suspensions.

3.      Patient Acceptance: Studies are necessary to determine patient acceptance and adherence to M3DIMAKER technology and the tailored-dose therapies it provides.

Regulatory Approval: M3DIMAKER technology must undergo rigorous testing and regulatory approval processes to ensure its safe and effective use in the healthcare industry.

IN M3DIMAKER technology involves the collection of patient data, calculation of the precise dose, 3D printing of the tailored-dose therapy, quality control, and packaging and delivery Patient Data Collection: Patient data, including medical history, current medications, and personal characteristics, are collected to determine the appropriate dose of medication required.

 

Dosage Calculation: The collected data is used to calculate the precise dose of medication required for each patient.

3D Printing: The calculated dose is then printed using 3D printing technology, creating a tailored dose therapy in a solid or semi-solid form.

Quality Control: The finished product is subjected to rigorous quality control measures to ensure its accuracy, consistency, and safety.

Packaging and Delivery: The tailored-dose therapy is packaged and delivered to the patient or healthcare provider, ready for administration.

The materials and methods used for the finished product. These steps ensure the safe and effective delivery of personalized medicines. Bottom of Form

 Improved Patient Outcomes: The results of clinical trials and real-world studies have shown that M3DIMAKER technology has the potential to improve patient outcomes by delivering the right dose of medication to the right patient at the right time.

 

Increased Adherence to Treatment: By delivering medications in a form that is personalized and easy to take, M3DIMAKER technology has been shown to increase patient adherence to treatment, leading to better outcomes and improved health.

Reduced Adverse Reactions: By delivering precise doses of medication, M3DIMAKER technology reduces the risk of adverse reactions, making treatments safer and more effective.

Cost-effectiveness: The technology has the potential to reduce the cost of developing new treatments by reducing the need for multiple clinical trials and speeding up the time it takes to bring personalized medicines to market.

Potential for Wider Access: M3DIMAKER's user-friendly and accessible nature has the potential to bring the benefits of personalized medicine to a wider range of patients, including those in under-resourced communities.

The results and discussion of M3DIMAKER technology demonstrate its potential to improve patient outcomes, increase adherence to treatment, reduce adverse reactions, be cost-effective, and bring personalized medicine to a wider range of patients. However, further studies are necessary to fully realize its potential and ensure its safe and effective use in the healthcare industry.

M3DIMAKER is a breakthrough technology that has the potential to transform the way personalized medicines are developed and delivered.

With its precision dosing, improved patient outcomes, cost-effectiveness, and ease of use M3DIMAKER has the power to revolutionize healthcare and bring the benefits of personalized medicine to millions of patients around the world

References: 1. A comprehensive overview of extended release oral dosage forms manufactured through hot melt extrusion and its combination with 3D printing Nour Nashed , Matthew Lam , Ali Nokhodchi * Pharmaceutics Research Laboratory, School of Life Sciences, University of Sussex, Brighton BN1 9QJ, UK

2. 3D Printing Technology in Drug Delivery: Recent Progress and Application

Sabna Kotta1,*, Anroop Nair2and Nimer Alsabeelah11College of Pharmacy and Dentistry, Buraydah Private Colleges, Buraydah, Saudi Arabia; 2College of Clinical Pharmacy, King Faisal University, Al Ahsa, Saudi Arabia.

3. Shaping the future: recent advances of 3D printing

in drug delivery and healthcare

Sarah J Trenfield, Atheer Awad, Christine M Madla, Grace B Hatton, Jack

Firth, Alvaro Goyanes, Simon Gaisford & Abdul W Basit

To cite this article: Sarah J Trenfield, Atheer Awad, Christine M Madla, Grace B Hatton, Jack

Firth, Alvaro Goyanes, Simon Gaisford & Abdul W Basit (2019): Shaping the future: recent.

 

Location: India

Comments

Post a Comment

Popular posts from this blog

"Mechanistic Insights into Androgen Excess and Insulin Resistance in PCOS: Preclinical Evidence and Alternative Models for Translational Research"

Image
  Introduction:   Polycystic ovary syndrome (PCOS) is a complex endocrine, metabolic, and reproductive disorder affecting 6–20% of reproductive-age women worldwide. A hallmark of PCOS is androgen excess , which plays a crucial role in its pathophysiology, along with insulin resistance (IR). These factors contribute to reproductive dysfunction, metabolic abnormalities, and long-term health risks such as type 2 diabetes and cardiovascular diseases. Despite extensive research, the exact mechanisms underlying PCOS remain unclear, necessitating further exploration of androgen metabolism, insulin signaling, and alternative therapeutic strategies. Methods: This synthesizes findings from preclinical studies (in vivo and in vitro models) and computational approaches to elucidate the role of androgens and insulin resistance in PCOS. ·         Animal Models: Insights from rodent models of hyperandrogenism and insulin resistance (e.g., postnatal...
Read more

The impact on pregnant people infected with the severe acute respiratory syndrome coronavirus 2 SARS-CoV-2) may be asymptomatic or symptomatic analysis by Saptadeep Nandi

Image
  The impact on pregnant people infected with the severe acute respiratory syndrome coronavirus 2 SARS-CoV-2) may be asymptomatic or symptomatic. Those who are symptomatic appear to be at increased risk for developing severe squeal of coronavirus disease 2019 (COVID-19) compared with nonpregnant reproductive-aged females. Need for the study:-  Diagnosis:- These physiologic changes make distinguishing pulmonary pathology difficult during pregnancy. This difficulty is heightened by the fact that COVID-19 infection has a wide array of presenting signs of symptoms. COVID-19 symptoms in pregnancy are similar to infections that occur in the general population with respect to presenting symptoms of cough (52%) and shortness of breath (30%). Pregnant women, however, were less likely to report symptoms of headache (41%), fever (34%), chills (38%), and diarrhea (14%) compared to the general population [5]. The other presenting symptoms, although less common, of COVID-19 infection, inclu...
Read more